AlloVir (ALVR) Competitors

$5.53 +0.07 (+1.28%)

As of 05/4/2026

ALVR vs. AARD, CRDF, VRCA, IFRX, and ASRT

Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Aardvark Therapeutics (AARD), Cardiff Oncology (CRDF), Verrica Pharmaceuticals (VRCA), InflaRx (IFRX), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry.

How does AlloVir compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

: Aardvark Therapeutics currently has a consensus target price of $22.60, suggesting a potential upside of 313.16%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than AlloVir.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aardvark Therapeutics
1 Sell rating(s)
4 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.62
AlloVir
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Aardvark Therapeutics' return on equity of -44.59% beat AlloVir's return on equity.
Company Net Margins Return on Equity Return on Assets
Aardvark Therapeutics N/A -44.59% -41.51%
AlloVir N/A -71.03% -61.27%
: Aardvark Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aardvark Therapeutics N/A N/A -$57.59M -$2.93 N/A
AlloVir N/A N/A -$190.42M -$20.23 N/A
: Aardvark Therapeutics has a beta of 5.11, indicating that its stock price is 411% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
: 66.1% of AlloVir shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: In the previous week, Aardvark Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Aardvark Therapeutics and 0 mentions for AlloVir. Aardvark Therapeutics' average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.
Company Overall Sentiment
Aardvark Therapeutics Neutral
AlloVir Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.62
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-44.59%	-41.51%
AlloVir	N/A	-71.03%	-61.27%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$2.93	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
AlloVir	Neutral

Summary

Aardvark Therapeutics beats AlloVir on 10 of the 13 factors compared between the two stocks.

How does AlloVir compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

: AlloVir has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. AlloVir's return on equity of -71.03% beat Cardiff Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Cardiff Oncology -7,733.22% -82.01% -64.09%
AlloVir N/A -71.03% -61.27%
: Cardiff Oncology has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
: In the previous week, Cardiff Oncology's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.
Company Overall Sentiment
Cardiff Oncology Neutral
AlloVir Neutral
: Cardiff Oncology has higher revenue and earnings than AlloVir. Cardiff Oncology is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardiff Oncology $593K 184.47 -$45.85M -$0.69 N/A
AlloVir N/A N/A -$190.42M -$20.23 N/A
: Cardiff Oncology currently has a consensus target price of $10.10, indicating a potential upside of 531.25%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cardiff Oncology is more favorable than AlloVir.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
AlloVir
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 7.7% of Cardiff Oncology shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%
AlloVir	N/A	-71.03%	-61.27%

Company	Overall Sentiment
Cardiff Oncology	Neutral
AlloVir	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$593K	184.47	-$45.85M	-$0.69	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cardiff Oncology beats AlloVir on 7 of the 13 factors compared between the two stocks.

How does AlloVir compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

: Verrica Pharmaceuticals has higher revenue and earnings than AlloVir. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verrica Pharmaceuticals $35.58M 3.46 -$17.89M -$1.58 N/A
AlloVir N/A N/A -$190.42M -$20.23 N/A
: Verrica Pharmaceuticals currently has a consensus target price of $17.00, indicating a potential upside of 137.43%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than AlloVir.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verrica Pharmaceuticals
2 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
1.75
AlloVir
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: AlloVir has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -50.27%. Verrica Pharmaceuticals' return on equity of 0.00% beat AlloVir's return on equity.
Company Net Margins Return on Equity Return on Assets
Verrica Pharmaceuticals -50.27% N/A -40.08%
AlloVir N/A -71.03% -61.27%
: 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Verrica Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
: In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than AlloVir. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 0 mentions for AlloVir. Verrica Pharmaceuticals' average media sentiment score of 1.95 beat AlloVir's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
Verrica Pharmaceuticals Very Positive
AlloVir Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	3.46	-$17.89M	-$1.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-50.27%	N/A	-40.08%
AlloVir	N/A	-71.03%	-61.27%

Company	Overall Sentiment
Verrica Pharmaceuticals	Very Positive
AlloVir	Neutral

Summary

Verrica Pharmaceuticals beats AlloVir on 12 of the 15 factors compared between the two stocks.

How does AlloVir compare to InflaRx?

AlloVir (NASDAQ:ALVR) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

: AlloVir's return on equity of -71.03% beat InflaRx's return on equity.
Company Net Margins Return on Equity Return on Assets
AlloVir N/A -71.03% -61.27%
InflaRx N/A -80.51% -61.36%
: InflaRx has a consensus target price of $5.80, indicating a potential upside of 194.42%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than AlloVir.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AlloVir
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
InflaRx
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
: InflaRx has higher revenue and earnings than AlloVir. InflaRx is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AlloVir N/A N/A -$190.42M -$20.23 N/A
InflaRx $29.33K 4,855.52 -$51.63M -$0.76 N/A
: In the previous week, InflaRx had 8 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for InflaRx and 0 mentions for AlloVir. InflaRx's average media sentiment score of 0.56 beat AlloVir's score of 0.00 indicating that InflaRx is being referred to more favorably in the news media.
Company Overall Sentiment
AlloVir Neutral
InflaRx Positive
: 66.1% of AlloVir shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
InflaRx	N/A	-80.51%	-61.36%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
InflaRx	$29.33K	4,855.52	-$51.63M	-$0.76	N/A

Company	Overall Sentiment
AlloVir	Neutral
InflaRx	Positive

Summary

InflaRx beats AlloVir on 9 of the 14 factors compared between the two stocks.

How does AlloVir compare to Assertio?

Assertio (NASDAQ:ASRT) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

: 49.0% of Assertio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 5.7% of Assertio shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: AlloVir has a net margin of 0.00% compared to Assertio's net margin of -25.59%. Assertio's return on equity of -30.26% beat AlloVir's return on equity.
Company Net Margins Return on Equity Return on Assets
Assertio -25.59% -30.26% -10.59%
AlloVir N/A -71.03% -61.27%
: Assertio currently has a consensus target price of $19.90, indicating a potential downside of 10.20%. Given Assertio's stronger consensus rating and higher probable upside, analysts plainly believe Assertio is more favorable than AlloVir.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assertio
1 Sell rating(s)
4 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
AlloVir
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Assertio has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.
: Assertio has higher revenue and earnings than AlloVir. Assertio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Assertio $118.71M 1.20 -$30.38M -$4.86 N/A
AlloVir N/A N/A -$190.42M -$20.23 N/A
: In the previous week, Assertio had 8 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for Assertio and 0 mentions for AlloVir. Assertio's average media sentiment score of 0.65 beat AlloVir's score of 0.00 indicating that Assertio is being referred to more favorably in the media.
Company Overall Sentiment
Assertio Positive
AlloVir Neutral

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-25.59%	-30.26%	-10.59%
AlloVir	N/A	-71.03%	-61.27%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.20	-$30.38M	-$4.86	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Company	Overall Sentiment
Assertio	Positive
AlloVir	Neutral

Summary

Assertio beats AlloVir on 10 of the 15 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.89M	$328.16M	$6.25B	$11.87B
Dividend Yield	N/A	N/A	2.73%	5.21%
P/E Ratio	-0.27	N/A	29.04	28.47
Price / Sales	N/A	189.48	476.61	60.92
Price / Cash	N/A	22.44	27.62	36.52
Price / Book	0.19	4.73	9.67	6.67
Net Income	-$190.42M	-$132.96M	$3.55B	$332.53M
7 Day Performance	-8.14%	7.60%	1.70%	2.01%
1 Month Performance	-4.49%	4.61%	5.62%	9.19%
1 Year Performance	-5.15%	37.44%	34.41%	39.59%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$5.53 +1.3%	N/A	N/A	$27.89M	N/A	N/A	110	High Trading Volume
AARD Aardvark Therapeutics	1.9357 of 5 stars	$5.59 +1.3%	$22.60 +304.3%	N/A	$120.43M	N/A	N/A	18
CRDF Cardiff Oncology	0.9242 of 5 stars	$1.68 -2.3%	$10.10 +501.2%	N/A	$117.60M	$590K	N/A	20
VRCA Verrica Pharmaceuticals	2.0072 of 5 stars	$6.53 -4.3%	$17.00 +160.3%	N/A	$117.25M	$35.58M	N/A	40	News Coverage Positive News Upcoming Earnings
IFRX InflaRx	3.6036 of 5 stars	$1.67 +3.7%	$5.80 +247.3%	N/A	$116.39M	$30K	N/A	60	News Coverage Upcoming Earnings High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors

ALVR vs. AARD, CRDF, VRCA, IFRX, and ASRT

How does AlloVir compare to Aardvark Therapeutics?

Summary

How does AlloVir compare to Cardiff Oncology?

Summary

How does AlloVir compare to Verrica Pharmaceuticals?

Summary

How does AlloVir compare to InflaRx?

Summary

How does AlloVir compare to Assertio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AlloVir (ALVR) Competitors

ALVR vs. AARD, CRDF, VRCA, IFRX, and ASRT

How does AlloVir compare to Aardvark Therapeutics?

Summary

How does AlloVir compare to Cardiff Oncology?

Summary

How does AlloVir compare to Verrica Pharmaceuticals?

Summary

How does AlloVir compare to InflaRx?

Summary

How does AlloVir compare to Assertio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVR vs. The Competition

AlloVir Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools